Recent news on Nipent

SuperGen Reports 2007 First Quarter Financial Results  -  May 2, 2007
Earthtimes.orgThe decrease in net product revenue during the 2007 first quarter is primarily due to the sale of the Company's North American rights for Nipent(R)

Nipent(R) Acquisition by Hospira is Complete  -  Apr 5, 2007
Drug Newswire (press release),Both transactions taken together complete our sale of all rights to Nipent. Total consideration from both transactions could total US$42 million.

Nipent(R) Acquisition by Hospira is Complete  -  Apr 3, 2007
Earthtimes.orgDUBLIN, Calif., April 3 -- SuperGen Inc. today announced that it closed on the sale of the remaining worldwide rights for Nipent(R) (pentostatin for

SuperGen Inc Closes Nipent Rights Sale  -  Apr 3, 2007
New Age Media Concepts (press release)LOS ANGELES, CA, (NAMC) - The pharmaceutical company SuperGen Inc. (NASDAQ:SUPG) has finally closed on the sale of the remaining worldwide rights for Nipent

SuperGen Reports 2006 Fourth Quarter and Year-End Financial Results  -  Mar 28, 2007
Drug Newswire (press release),The decrease in net product revenue during the 2006 fourth quarter is primarily due to the sale of the Company's North American rights for Nipent and

SuperGen completes $8 million sale of leukemia drug rights  -  Apr 4, 2007
Bizjournals.com,SuperGen Inc. has closed on the sale of remaining worldwide rights to its leukemia drug Nipent to the specialty pharmaceutical company Hospira Inc. for $8

Gap shares up; worst may be over  -  Apr 11, 2007
Contra Costa Times,Pharmaceutical company SuperGen Inc. of Dublin sold its remaining worldwide rights of its leukemia drug Nipent to pharmaceutical company Hospira Inc. for $8

SuperGen Reports 2006 Fourth Quarter and Year-End Financial Results  -  Mar 14, 2007
PR-Inside.com (Pressemitteilung),...from an acquisition, a reduction in Nipent(R) (pentostatin for injection) and Surface Safe(R) net product revenue due to the sale of the US commercial

SuperGen Reports 2006 Fourth Quarter and Year-End Financial Results  -  Mar 14, 2007
PR Newswire (press release),A deferred gain on the sale of the North American rights for Nipent and Surface Safe to Mayne Pharma in the amount of $11.8 million has been recorded by the

SuperGen Q4 Loss Widens; Revenue Plummets - Update  -  Mar 14, 2007
Trading Markets,The decrease in net product revenue during the 2006 fourth quarter is primarily due to the sale of the company's North American rights for Nipent and

SuperGen's Q4, full-year loss increases  -  Mar 15, 2007
Bizjournals.com,...was due to the sale of North American rights for the drug Nipent and the Surface Safe towelette cleaning system to Mayne Pharma, which took effect Aug.

Increased Risk of Second Malignancies in Hairy Cell Leukemia  -  Feb 15, 2007
Cancer Consultants (press release),However, other treatments such as Nipent® (deoxycoformycin, pentostatin), interferon-alpha, splenectomy, and Rituxan® are also effective.

Mayne Pharma Acquires Remaining Nipent Rights  -  Nov 27, 2006
PharmaLive.com (press release),Nipent(R) is approved for patients with hairy-cell leukaemia. Sales of Nipent(R) in Europe last year were almost US $5 million with France, Germany, Greece,

Mayne Pharma to Acquire Remaining Worldwide Rights to Nipent From ...  -  Nov 27, 2006
StreetInsider.com (subscription),Mayne Pharma Ltd. and SuperGen Inc. (Nasdaq: SUPG) announced that Mayne has agreed to acquire the remaining worldwide rights to Nipent for a total

SuperGen to sell remaining leukemia drug rights for $8M  -  Nov 28, 2006
Bizjournals.com,SuperGen Inc. and Mayne Pharma Ltd. announced Monday that Mayne will buy the remaining worldwide rights for SuperGen's leukemia drug Nipent for $8 million.

SuperGen to sell remaining leukemia drug rights for $8M  -  Nov 27, 2006
San Francisco Business Times,SuperGen Inc. said Monday that Mayne Pharma Ltd. will buy the remaining worldwide rights for SuperGen's leukemia drug Nipent for $8 million.

Mayne Acquires Remaining Rights to Hairy-Cell Leukemia Drug  -  Nov 27, 2006
Genetic Engineering News (press release),In August 2006, Mayne paid $34 million for the North American rights to Nipent® (pentostatin for injection). SuperGen will receive approximately $3.75

Market Report -- In Play (SUPG)  -  Nov 27, 2006
MSN MoneySuperGen: Mayne Pharma acquires remaining Nipent rights for $8 mln Mayne Pharma and SUPG announced today that Mayne has agreed to acquire the remaining

Oakland band finalist in YouTube contest  -  Dec 2, 2006
Contra Costa Times,Mayne Pharma Ltd. of Australia has agreed to acquire the remaining worldwide rights to Dublin-based SuperGen Inc.'s leukemia drug Nipent for $8 million.

(PRN) - 'Wild Griefer' Music Video Wins There.com's Virtual Film ...  -  Nov 27, 2006
Bolsamania.com,...(PRN) - Mayne Pharma Acquires Remaining Nipent(R) Rights ... [+]. (PRN) - Diana Shipping Inc. Announces Time Charter Contract For MV Dione and Accepts Offer

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional